Bioduro Go to mainpage


Michael Thompson

McMaster University – Associate Dean and Professor of Chemical Engineering

Presentation: Developments in Twin-Screw Granulation

Date: May 26th

Dr. Michael Thompson is a Professor of Chemical Engineering and Associate Dean of Engineering at
McMaster University in Canada. His research group looks at processes related to polymers or particulate
production, to develop new manufacturing solutions for the industries of polymer, food,
pharmaceutical, and energy.  The group at McMaster is one of the earliest research contributors to the
field, beginning back in 2008, and has been responsible for much of the screw design and wetting
practices used today.  The group enjoys close collaborations with a range of experts in the drug and
excipient community and remains committed to seeing broader deployment of twin-screw granulation
within the industry.


Chad Brown

Dr. Chad Brown

Merck – Executive Director and Global Head, Pharmaceutical Sciences

Presentation: Hot Melt Extrusion as a Key Enabler of Developing Products of
Low Solubility Compounds

Date: June 2nd

Chad Brown is the Executive Director and Global Head of the Merck Animal Health Pharmaceutical Sciences group located in Rahway, NJ, USA. His responsibilities include oversight of Formulation, Analytical and Packaging R&D from early discovery to commercial launch. Chad has 17 years of drug product development experience. He joined Merck in 2007 in the Merck Research Laboratories in Human Health and led the Oral Formulation Sciences and Technology group in Human Health. During this tenure, he became a subject matter expert in solid dispersion manufacturing, specifically hot melt extrusion and served on the board of The Society of Plastic Engineers Extrusion Division. He has been fortunate to be involved with several publications, patents and product launches using this technology. Chad holds a PhD from the University of Washington in Bioengineering and a BS degree from Colorado State University in Chemical Engineering.


Andy Birkmire

GEA – Process Development Manager

Presentation: Successful Strategies for Developing a Continuous Manufacturing Process

Date: June 9th

Andrew Birkmire is the Process Development Manager for GEA Process Engineering, Inc., a world leader in Pharmaceutical manufacturing technology. He has more than 20 years of experience with Pharmaceutical Batch and Continuous processes, including feeding, blending, granulation, drying, and coating. He currently runs the Pharmaceutical Technology Center in Columbia, MD.


Dr. John Vrettos

Enteris BioPharma – Principal Scientist in Formulation Development

Presentation: Breaking Through the Barriers of Oral Biologics

Date: June 16th

Dr. John Vrettos joined Enteris BioPharma in July 2013 as a Principal Scientist in Formulation Development. He is responsible for development programs for the oral delivery of peptides and poorly-permeable small molecules from feasibility through clinical trials. Previously, Dr. Vrettos was with Unigene Laboratories, advancing formulations to enable the oral delivery of peptides. Dr. Vrettos gained much experience with solid oral formulation development while a Principal Scientist in Technical R&D at Novartis Pharmaceuticals from 2008 to 2012. Prior to that, he was a Senior Scientist in the Pharmaceutical Sciences department at Human Genome Sciences. Dr. Vrettos received his Ph.D. in biophysical chemistry from Yale University in 2001 and was a National Research Council Postdoctoral Fellow at NIST in the Biomolecular Materials group from 2002-2003.


Dr. Harsh Chauhan

Creighton University – Associate Professor, Pharmacy

Presentation: Formulation Considerations for development of Ternary Solid Dispersions

Date: June 23rd

Dr. Chauhan is an Associate Professor in Pharmaceutical Sciences at Creighton University, NE, USA; with a research lab working in the area of developing novel drug delivery systems for poorly soluble compounds. He completed his PhD from MCPHS University, Boston, MA. He had published more than 25 peer reviewed article, five book chapters and presented around 50 posters in national and international conferences. He serves as reviewer and editorial board in many reputed pharmacy journals. He is a member of American Association of Pharmaceutical Scientist (AAPS) and American Chemical Society (ACS). His profile can be found here.


Dr. Daniel Treffer

Melt Prep – CEO and Founder

Presentation: Rapid and lossless prototyping of HME formulations in the milligram to gram scale via Vacuum Compression Molding

Date: June 30th

Daniel Treffer is the founder and CEO of MeltPrep GmbH. A start-up company founded in 2016 which develops equipment for sample preparation. The company is based on his findings, which he obtained during his PhD in the field of pharmaceutical engineering. His work was supervised by Professor Khinast at the RCPE in Graz, where he faced several challenges in hot-melt extrusion development projects and recognised the strong need for novel tools for faster and lossless drug formulation developments. He patented the innovative vacuum compression molding (VCM) technology in 2014.
He also established two new product lines within his company. First, the VChamber, which turns any hot plate into a vacuum oven, and second ExtruVis, a technology for straight-forward and precise residence time distribution measurement.

During his career, Daniel has authored & published several scientific papers, contributed to the scientific textbook “Melt Extrusion by Dr. Repka” and is a coveted speaker at different conference talks all over the world.

His mission is to simplify drug development processes in order to enable pharma companies to bring much-needed drugs to the market as fast as possible.


Jim Marjeram

O’Hara Tech – Technology Director

Presentation: Advantages of Continuous Tablet Coating

Date: September 8th

Jim Marjeram is a graduate of Humber College with a specialty in Electro-Mechanical Engineering Technology. Jim has worked in the pharmaceutical industry for more than 30 years, concentrating on solid dosage solutions. Most of Jim’s career has been with O’Hara Technologies Inc. which has grown from local engineering firm to world class supplier of engineered pharmaceutical tablet coating and process systems during Jim’s tenure with the organization. Jim has served the company in diverse roles from product development to his current role as Sales Director. Throughout that time Jim has developed several patents and patents-pending in the area of continuous tablet coating. Jim can be contacted at jim.marjeram@oharatech.com.


Seth Forster

Merck – Associate Principal Scientist

Presentation: Long-Acting Implants: Design for Durable Drug Delivery

Date: August 4th

Seth Forster is an Associate Principal Scientist in the Pharmaceutical Commercialization Technology department of Merck Manufacturing Division, based in West Point, PA. He is focused on development and scale-up of novel pharmaceutical dosage forms and process technology, especially for long-acting drug-eluting implants and dry powder inhalers. Seth has a BS in Chemical Engineering from Purdue University and an MS in Pharmaceutics from Temple University. He has been developing pharmaceutical products since 2006.


Dr. John Shelley

Schrodinger – Schrodinger Fellow

Presentation: Formulation Development for Small Molecules and Biologics Enhancements with Molecular Modeling

Date: July 28th

John Shelley, PhD, has been a software developer and product manager at Schrödinger for approximately 20 years. John was promoted to Fellow based upon his work on software products for small-molecule drug design. Over the last 6 years his work has shifted to modeling related to drug formulation particularly structured solutions including liposomes, polymersomes and protein solutions.


Dr. Andrea Browning

Schrodinger – Product Manager

Presentation: Formulation Development for Small Molecules and Biologics Enhancements with Molecular Modeling

Date: July 28th

Andrea Browning is responsible for leading efforts related to polymeric materials simulation in Schrödinger Materials Science and joined Schrödinger in 2017. Prior to joining Schrödinger, she was a lead research engineer and project manager at The Boeing Company. She brings a decade of experience in connecting industrial, engineering problems to root materials issues and how simulations can be used to inform industrial decisions.


Dr. Dedong Wu

AstraZeneca – Senior Scientist

Presentation: Improving Bioavailability by Prodrug Approach

Date: September 1st

Dedong Wu is a senior scientist in AstraZeneca Pharmaceutical Science to provide expertise in the areas of predictive pharmaceutics, drug substance form selection, preformulation, enabling formulation and drug delivery for both early-stage drug candidate design/assessment and commercial drug product development. He had worked in Bristol-Myers Squibb for 5 years before he joined Astrazeneca in 2005. Dedong Wu received his Ph.D. in physical chemistry and has published more than 80 scientific manuscripts.


Chandra Kelley

Pfanstiehl – Director of Business Development

Presentation: Key Considerations in Accelerating Biopharma Formulation Development

Date: August 11th

Chandra Kelley has been the Director of Business Development at Pfanstiehl, Inc. since 2016, has more than twenty years of experience in the Biopharma industry and a BS in Biology from PLNU in San Diego.


Dr. Feng Zhang

UT Austin – Assistant Professor in Pharmaceutics

Presentation: Hot-melt extrusion to prepare amorphous solid dispersions: key concepts and common misperceptions

Date: July 7th

Feng Zhang is an assistant professor at the University of Texas at Austin. He received his Ph.D. in pharmaceutics from the University of Texas at Austin. He worked in the industry for 14 years prior to joining the department of pharmaceutics at the University of Texas at Austin in 2014. He was the Director of Product Development at PharmaForm (now part of BioDuro) from 2007 to 2010 and Senior Scientist in the Formulation and Process development department at Gilead from 2011 to 2013. Zhang has been conducting research and product development using twin-screw extrusion process since 1994.

His principal research interest at UT Austin is in twin-screw extrusion processing for continuous granulation, bioavailability enhancement, and controlled release drug delivery. He is the editor of 2nd edition of “Pharmaceutical Extrusion Technology”, published in 2018. He has authored four book chapters on twin-screw extrusion process. He has published 60 peer-reviewed papers articles. He is also inventor on 12 issued patents covering a wide range of drug delivery systems. He serves on the editorial board of AAPS PharmSci Tech and North American editor for Journal of Drug Delivery Science and Technology.


Dr. Xiaohu Deng

Viracta – Sr. Vice President of Product Development

Presentation: Phase-appropriate CMC Strategies in Drug Product Development

Date: July 14th

Dr. Deng is a Sr. Vice President of Product Development at Viracta Therapeutics, overseeing the overall product development strategy and execution. Prior to Viracta, Dr. Deng was Senior Director, Head of CMC at Kura Oncology, Inc. and Wellspring Biosciences, leading the CMC function – including development, manufacture, quality control, and clinical supply – of multiple programs through various phases of development (I, II and III and registrational).   Dr. Deng started his industry career at Janssen Pharmaceutical Companies of Johnson & Johnson in various roles of increasing responsibility associated with process chemistry R&D, CRO management, and project management of discovery/preclinical development.  He has more than 60 peer-reviewed journal publications, book chapter, abstracts and patents to his credit.  Dr. Deng holds a Ph.D. in organic chemistry from Emory University and MS and BS in chemistry from Fudan University.


Dr. Yi-Ling Hsieh

AbbVie – Senior Scientist

Presentation: Lipid-Based Formulation – The Impact on Biopharmaceutics and Patient Centricity

Date: July 21st

Dr. Yi-Ling Hsieh is a Senior Scientist in Early Development in AbbVie. She has extensive experience in formulation development for early and late stage projects. She currently leads the lipid-based formulation platform development in AbbVie (Legacy Allergan) and investigates the impact of formulation design on biopharmaceutics. Prior to her current position, she led the solid-state characterization effort for the small and large molecule inhalation formulation in Novartis to support the development activities from pre-clinical stage to NDA submission. She also gained wide-ranging industry experience, including material characterization, novel enabling formulations, and regulatory quality compliance from her prior experience in Pfizer, Schering-Plough and Bristol-Myers Squibb. She authored several peer-reviewed publications with the focus of salt stability and the precipitation and supersaturation behavior of drug molecules. Dr. Hsieh earned her Ph.D. degree in Pharmaceutics and B.S. degree in Pharmaceutical Sciences from Purdue University – West Lafayette.

Dr. Abu Serajuddin

St. John’s University – Professor of Industrial Pharmacy

Presentation: Development of HPMCAS-based amorphous solid dispersions by melt extrusion

Date: August 18th

Abu Serajuddin, PhD, is Professor of Industrial Pharmacy at St. John’s University, Queens, New York, USA. Prior to joining academia in 2008, he worked in the pharmaceutical industry for 32 years in scientific and managerial positions. In his latest positions in the industry, he served as Executive Director and the US Head of Pharmaceutical R&D at Novartis Pharmaceutical Corp. Currently, at St. John’s University, he has built a world-class teaching and research program dedicated to the development of drug delivery systems and pharmaceutical processing technologies, including melt extrusion. He has published over 120 papers and book chapters, and he is a coinventor in 13 patents. He also made 145 invited presentations in national and international conferences. In recognition of his scientific and professional achievements, he was elected Fellow of American Pharmacists Association (APhA) and American Association of Pharmaceutical Scientists (AAPS).  AAPS also recognized him with 3 of its highest awards, namely, AAPS Research Achievement Award in Formulation Design and Development in 2010, AAPS Research Achievement Award in Manufacturing Science & Engineering in 2014, and the AAPS Lipid-based Drug Delivery Outstanding Research Award in 2015. For his academic and research excellence as a member of the faculty, St. John’s University bestowed him the University Medal for Outstanding Achievement in 2019.

Sean Mcmahon

Ashland – Professor of Industrial Pharmacy

Presentation: Business Development and Technical Manager

Date: TBD

Dr. Seán McMahon is the Business and Technical Manager for the ViatelTM bioresorbable polymer portfolio at Ashland, supporting customers with key excipients/materials and technical solutions in the development of extended release parenteral drug delivery formulations, medical devices, tissue engineering scaffolds and cosmetics.

He joined Ashland as part of the Vornia Ltd. acquisition in 2018 where he previously held responsibility for the company’s major business functions in his role as CEO. During his time at Vornia Ltd., he led development of the company’s major intellectual property platform for production of bioresorbable polymers. He has extensive knowledge of bioresorbable polymer design, chemistry and processing technologies used in medical applications. This experience comes from working on large research and commercial projects delivering bioresorbable polymer-based solutions for orthopedic, cardiovascular, neurological, oncology, wound-care, dental, ophthalmic, regenerative medicine and wider drug delivery technologies.

Dr. McMahon has published several research/review papers on polymer design for medical applications. He obtained his B.Eng. and M.Sc. from the National University of Ireland, Galway (NUIG) and his Ph.D. from the School of Medicine and Medical Sciences at the University College Dublin (UCD), Ireland.


David Preston
David Preston


David Preston has had 38 years of healthcare experience with publicky Traded and Private companies in the fields of Phammaceuticals, Animal Health and Biotechnology as a Board Member. The last 30 years of his xperience has been in China, Taiwan and Hong Kong building successful igh growth businesses. David Has been Chaiman and CEO for Greater China for Sanofi and Boehringer – Ingelheim as well as the Janssen Corporation since 1991 in China. During this time he build high Growth ousinesses in China through diversified strategies in Innovative Pharmaceuticals. branded Generics. Biotechnology. and Animal Healthcare.

Key highlights in this period indluded building of the first Westem Multinational Biotechnoloqy C.M.O. facility as well as obtaining the first Test CM.OJ MAHI license. Establishment of a number of High tech Vaccine Plants, and R and D facilities in in the field of Animal Health. Signing and development of numerous JV’s as well as Wholly owned Subsidiaries. Mergers and Acquisitions across Phamaceutical’s. Animal Health. and Biotechnology industries

David’s achievement’s in the Healthcare industry and it Growth and development in China is widely recognized By the Chinese Govemnment and the City of Shanghai In 2013 he was awarded the Silver Magnolia ollowed in 2015 the Gold Magnolia award. This was then followed by being awarded in 2017 the Honorary Citizen of Shanghai by 40th People’s Municipal Congress of Shanghai. David Holds a Business Science Degree

This will close in 0 seconds

Filippo de Vecchi

Director, Advent Partner

Filippo de Vecchi joined Advent in February 2000. He started in the Advent São Paulo office, then moved to Milan in 2002, in 2012 set up the Advent office in Shanghai and in 2016 set up the Hong Kong office. Before joining Advent, he was a senior consultant with Value Partners, in São Paulo and Milan, focusing on strategy and organization in the automotive, energy, cable and media sectors. He began his career at Wasserstein Perella & Co., working as an analyst in the Mergers and Acquisitions department in London and New York. Filippo holds an undergraduate degree cum laude in Economics, with a major in Business Administration, from the LUISS University and an MBA from Columbia Business School, where he currently serves as a member of the Board of Overseers.

This will close in 0 seconds

Andrew Li
Andrew Li

Director, Advent Partner

Andrew Li joined Advent in 2012. He previously worked at Warburg Pincus, HSBC PE, Solera Capital and Credit Suisse where he focused on the retail and consumer, healthcare, industrial, and energy sectors. Andrew has worked in finance and private equity throughout the U.S. and China since 1999. Andrew holds a BA from Middlebury College and an MBA from Harvard Business School.    

This will close in 0 seconds

Michael Miltenberger
Michael Miltenberger

Director, Advent Partner

Michael Miltenberger  joined Advent in 2011 as an associate on the healthcare team. Following business school, he rejoined Advent’s Boston office, focusing on healthcare investments. Prior to Advent, Michael was a consultant at McKinsey & Company in their Washington DC office, serving a range of healthcare and private equity clients. Michael earned a BA, cum laude, from Harvard College and an MBA from Harvard Business School, graduating with High Distinction as a Baker Scholar and a Harvey Fellow.

This will close in 0 seconds

Masood Tayebi
Masood Tayebi, PhD

Director, Operating Partner

Dr. Masood Tayebi is the Founder of BioDuro. He currently serves as CEO of a nationwide real estate portfolio and is a Partner and Chief Executive Officer of the Bridgewest Group. Prior to BioDuro, Dr. Tayebi was Co-Founder and Chairman of Wireless Facilities, Inc. (NASDAQ: WFI), a global leader in telecommunications outsourcing.

  • Co-Founder of Wireless Facilities, Inc.

  • Co-Founder of BioAtla, LLC

  • Recipient of the Ernst and Young 2000 Entrepreneur of the Year award in San Diego

This will close in 0 seconds

Kewen Jin
Kewen Jin, PhD

Director, Operating Partner

This will close in 0 seconds

Amit patel
Amit Patel

Director, Operating Partner

Amit Patel has twenty years of healthcare industry experience with publicly-traded, private equity-backed, and start-up companies in the capacity of executive, board member, advisor, and investor.  He is currently Executive Chairman of Azurity Pharmaceuticals (a NovaQuest Capital Management portfolio company) and a board member at BioDuro (Advent International portfolio company), Tergus Pharma (Great Point Partners portfolio company) and Calyptus Pharma.  Recently, Amit was SVP & President of Dosage Form Solutions at Capsugel, a KKR portfolio company (purchased from Pfizer in 2011 and sold to Lonza in 2017).   

Prior to Capsugel, he worked at Dr. Reddy’s Laboratories, Inc. as EVP & Head of North America, and SVP & Head of Global Corporate Development & Strategic Planning. Earlier, Amit was VP of Corporate Development at CTIS, Inc., and Co-founder & CEO of MedOnTime, Inc. (acquired by CTIS).  He started his career as a strategy consultant with Marakon Associates. Amit holds an M.B.A. degree from Harvard Business School, a B.S. degree in Economics from the Wharton School of Business, University of Pennsylvania, and a B.A.S. degree in Systems Engineering from the Moore School of Engineering, University of Pennsylvania.

This will close in 0 seconds

Haijun Dong
Haijun Dong

Chief Executive Officer

Dr. Haijun Dong currently serves as global CEO of BioDuro-Sundia. He previously was CEO for over 5 years at PharmaBlock Sciences Inc., a public company listed in the Shenzhen Stock Exchange (300725.SZ). The positions he held prior to PharmaBlock includes, among others, Senior Scientist at Boehringer Ingelheim Pharmaceuticals in Ridgefield, Connecticut; Senior Principal Scientist at Roche in Nutley, New Jersey; Head of DMPK and Drug Safety at Roche China R&D Company in Shanghai; Chief Operating Officer of Eli Lilly China R&D Center in Shanghai.

Dr. Dong received his PhD in organic chemistry from the University of Washington in Seattle, Washington, and MBA from China Europe International Business School in Shanghai. 

This will close in 0 seconds

Teo Nee Chuan
Teo Nee Chuan

Chief Financial Officer

Teo Nee Chuan joined us in May 2021 as chief financial officer. Prior to joining us, he was chief financial officer of Huazhu Group from November 2015 to May 2021, and was the chief financial officer for Rnomac International Limited, from November 2011 to August 2015. Mr. Teo worked in DDB Greater China Group, was appointed as the chief financial officer in September 2009, and was additionally appointed as the director of operations in January 2011. He previously served in Focus Media Group and was appointed as the financial deputy director in June 2007. Prior to that, from September 1994 to May 2007, Mr. Teo worked at Ernst & Young and Ernst & Young Business Services Ltd. in various positions in Kuala Lumpur and Toronto, including as a senior manager in the Transaction Advisory Services. Mr. Teo has been an independent director of 111, Inc. (a company listed on the NASDAQ, ticker symbol: YI) since September 2018. Mr. Teo received his Bachelor of Science in Accounting and Financial Analysis degree from The University of Warwick in the United Kingdom in July 1994. He is a Chartered Certified Accountant in the United Kingdom, who has obtained his qualification in July 1998 from The Association of Chartered Certified Accountants, and is a Certified Public Accountant in the United States and Hong Kong, who has obtained his qualification from American Institute of Certified Public Accountants in May 2002 and Hong Kong Society of Accountants in October 2003, respectively.

This will close in 0 seconds

TJ Deng, PhD

President, Discovery

Dr TJ Deng joined BioDuro in the initial stages of the company and helped BioDuro grow to an industry leading discovery services organization. He established and managed several scientific departments, including DMPK, before transitioning to a leader of the business and operations functions. Prior to joining BioDuro, Dr. Deng spent six years at PPD, in positions with increasing responsibilities from scientist to scientific manager.




  • Developed the extractable/leachable capabilities at PPD
  • 18 years industry experience

This will close in 0 seconds

Kent Payne
Kent M. Payne, PhD

Chief Executive Officer

Kent is distinguished as a business operator and leader in areas of sales, commercial manufacturing and product development. He has extensive executive experience in M&A as well as successfully running, start up, growth and turn around businesses. This includes both Fortune 500 and Private Equity environments. He combines strong business leadership, successful P&L track record, and technical background to strategically lead and grow enterprise value across Biotechnology and Pharmaceutical market segments. He has successfully led the geographic expansion of businesses into Europe, Asia, and South America in addition to the United States.  He currently serves as CEO for BioDuro-Sundia, LLC (an Advent International company). He also currently serves as a board member for Goodwin Biotechnologies (a Signet Healthcare company). 

Prior Roles

  • President, Global CMC Solutions BioDuro-Sundia, a global
  • CEO Socorro Pharmaceuticals, LLC, a generic pharmaceutical
  • President Americas, Qualicaps Inc.(a Mitsubishi Chemical Holdings subsidiary)
  • Principal Consultant and Partner at CoreFactor LLC, providing executive strategic, licensing and operational advisory services to clients.
  • Vice President/General Manager Catalent Pharma Solutions, Inc. (a Blackstone Group company formed in 2007, formerly part of Cardinal Health)
  • Progressive leadership responsibility at: Novartis, Monsanto and G.D. Searle.  

Prior Brand Position

  • Board Advisor Vitruvias Therapeutics
  • Board Member Qualicaps, Inc. (a wholly owned subsidiary of
    Mitsubishi Chemical Holdings)
  • Board member Technophar, Inc. (a wholly owned subsidiary of
    Mitsubishi Chemical Holdings)
  • Board Advisor, Corporate Strategy Office, Life Science Institute
    Inc. (a wholly owned subsidiary of Mitsubishi Chemical Holdings)
  • Non-executive Chair and Board Member PDS Biotechnology·        (PDSB: NASDAQ)

This will close in 0 seconds

John Phillips
John Phillips

Vice President, Business Development (US & EU)

Coming soon…



  • Coming soon…

This will close in 0 seconds

Roy Xu
Roy Xu

Chief Strategy Officer

Roy has over 25 years of healthcare industry experience.  He started his career as an orthopedic surgeon.  Roy joined Eli Lilly as a sales rep in 1997.  Since then he has had various roles in market research, business intelligence, BU head, strategy, regional general management, business development etc., both at Eli Lilly and Boehringer Ingelheim (BI).  Roy also spent more than two years in Germany where he was BI’s Director of Corporate Business and Enabling Strategy.

Roy obtained a bachelor’s degree in Clinical Medicine at Zhejiang Traditional Chinese Medicine University, and an MBA from Zhejiang University.



  • 25 years of healthcare industry experience including Eli Lily and Boehringer Ingelheim. 
  • Former Director of Corporate Business & Enabling Strategy at oehringer Ingelheim in Germany.

This will close in 0 seconds

San Diego

BioDuro- San Diego Facility

Our San Diego site is our corporate headquarters. The facility is home to BioDuro-Sundia’s drug product development technologies and has 9 GMP clean rooms. Development and manufacturing operations are conducted for projects up to Phase III clinical trials.

Size: 44,000 sq. ft.
Featured capabilites: Tableting, Coating, Hot Melt Extrusion, Spray Dried Dispersion

11011 Torreyana Rd.
San Diego
CA 92121
United States

This will close in 0 seconds


BioDuro Beijing

Operating since 2006, our Beijing site is home to BioDuro-Sundia’s first wet chemistry operations. With 300 regular fume hoods and 18 scale-up chemistry hoods the Beijing facility houses most of BioDuro’s chemistry operations, while also hosting labs for biology and monoclonal antibody discovery.

Size: 100,000 sq. ft. 
Featured capabilities: Radioactivity Lab, Monoclonal Antibody Discovery, Medicinal Chemistry

No. 29 Life Science Park Road
Changping District Beijing,
P.R. China

This will close in 0 seconds


BioDuro- Shanghai Facility

Established in 2012, BioDuro-Sundia’s Shanghai facility has been growing with its departments. The cutting edge facility contains labs for ADME, bioanalysis, in vitro assays and translational research. The site includes a 18,000 sq. ft vivarium and 20,000 sq. ft of office space.

Size: 92,000 sq. ft.
Featured capabilities: Scale-up Chemistry, Discovery Biology, DMPK, In Vivo Pharmacology

No. 233 North Fu Te Road
Waigaoqiao Free Trade Zone
Shanghai, 200131
P.R. China

This will close in 0 seconds

Cathy Yen
Cathy Yen

Director, Operating Partner

Cathy joined the Board of Directors of BioDuro-Sundia in 2020, with the Advent-led acquisition of Sundia and creation of BioDuro-Sundia. Prior to that, she was Chairman of the Board at Sundia Meditech Group, where she was the key architect of Sundia’s strategic vision and growth. Under her leadership, Sundia solidified its position as one of the leading pre-clinical CROs in China.

Prior to Sundia, Cathy had a distinguished career as a seasoned venture capitalist, having led numerous investments in high-growth companies in Asia. Cathy served as a Partner of AsiaVest Partners, TCW/YFY Ltd., a global venture capital firm, for over a decade, Vice President at Global Financial Services, Vice President at Crimson Ventures/Chinatrust Bank and Senior Manager at Fortune Capital. She brings over 20 years of experience in corporate finance, accounting, strategic planning and private equity investments. 

This will close in 0 seconds


Wuxi - BioDuro

Established in 2019, BioDuro-Sundia’s fully integrated discovery facility located at the heart of Jiangsu Wuxi Life Science & Technology Industrial Park with plans of growing staff to 1000+ scientists.

Size: 300,000 sq. ft.
Featured capabilities:
Discovery Chemistry & Biologics, Biology, DMPK, Pharmacology, CMC Services

no.1699,Huishan avenue
Huishan Economic 
Development Zone,Wuxi
P.R. China

This will close in 0 seconds


Hebei - Sundia

Established in 2011, this pilot plant this handles mg to kg scale up.

Size: 45,208 sq. ft.

Featured capabilities: SFFS Chemistry: mg to kg scale up
(150 hood)

238 Changjiang Road
Hebei province
P.R. China

This will close in 0 seconds


Taiwan Sundia

Our site in Taiwan supports Discovery Biology and Chemistry.

Size: 3,352sq.ft.
Featured capabilities: Chemistry;Biology

7F, No. 107, Sec. 4
Ren Ai Road,
Da-an District,
Taipei, Taiwan

This will close in 0 seconds


Bengbu - Sundia

Scheduled to open in fall of 2021, this site is designed to handle non-GMP manufacturing, advanced intermediates, GMP starting material(RSM) for IND enabling sttudies as well as clinical and commercial use. 

Size: 43,056 sq. ft.
Featured capabilities: Intermediates, GMP starting materials

Mohekou Industrial Park,
Huaishang District, Bengbu, 
Anhui province
P.R. China

This will close in 0 seconds


Shanghai Changli

Our Shanghai-Changli site supports FTE cheimistry and advanced Discovery Chemistry processes.

Size: 71,844 sq. ft.
Featured capabilities: Chiral Analytical Lab, Analytical and Purification Lab, NMR Lab, Synthetic Lab, Parallel Synthesis Lab, Flash Chromatography Lab..(380 hoods)

Building 8, 251 Faladi Road,
Zhangjiang Hi-Tech Park,
Shanghai, China
P.R. China

This will close in 0 seconds


Shanghai Halei

Opened in 2018, BioDuro-Sundia’s Shanghai-Halei contains facilities that support both Discovery and CMC parts of the drug development & manufacturing process. Facilities include amorphous dispersion techniques like SDD & Discovery Biology.

Size: 31,043 sq. ft.

Featured capabilities: Formulation : Preformulation, Wet Granulation, Compression, Tablet Coating, Fluid Bed Room, Spray Dryer, Hot Melt Extrusion, Dry Granulation Biology: Kinase selectivity, Cellular Assay, Compound Screen, Immune oncology service

Building 1, 917 Halei Road,
Zhangjiang Hi-Tech Park,
Shanghai, China

This will close in 0 seconds